<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001074</url>
  </required_header>
  <id_info>
    <org_study_id>202000134</org_study_id>
    <nct_id>NCT05001074</nct_id>
  </id_info>
  <brief_title>Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients</brief_title>
  <acronym>REVOLUTION</acronym>
  <official_title>Randomized Controlled Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heleen Grootjans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung transplantation is a life-saving option in patients with end-stage lung disease. The&#xD;
      introduction of calcineurin inhibitors has significantly improved long-term outcome in lung&#xD;
      transplantation. The most frequently used calcineurin inhibitor as maintenance therapy is&#xD;
      immediate release tacrolimus, dosed twice daily, which has shown to reduce both acute and&#xD;
      chronic rejection. However, a drawback to the administration of tacrolimus is its toxicity.&#xD;
      Especially progressive renal toxicity, new onset diabetes and hypertension contribute to the&#xD;
      high cardiovascular burdon in this patient group. Since a few years an once daily extended&#xD;
      release tacrolimus has been introduced in solid organ transplantation. The advantage of&#xD;
      extended release tacrolimus is its prolonged release and higher bioavailability than other&#xD;
      tacrolimus formulations. This result in lower peaks, more stable serum levels over 24 hours,&#xD;
      and less fluctuation of blood concentrations.&#xD;
&#xD;
      Long-term toxicity outcome of extended release tacrolimus after lung transplantation has not&#xD;
      been studied so far. Therefore the potential benefit of exteded release tacrolimus in de novo&#xD;
      and stable post-lung transplant recipients should be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung transplantation is a life-saving option in patients with end-stage lung disease. The&#xD;
      introduction of calcineurin inhibitors (CNI) has significantly improved long-term outcome in&#xD;
      lung transplantation. The most frequently used CNI as maintenance therapy is immediate&#xD;
      release tacrolimus, dosed twice daily, which has shown to reduce both acute and chronic&#xD;
      rejection. However, a drawback to the administration of tacrolimus is its toxicity.&#xD;
      Especially progressive renal toxicity, new onset diabetes and hypertension contribute to the&#xD;
      high cardiovascular burdon in this patient group. In lung transplant recipients the incidence&#xD;
      of severe renal impairment, new onset of diabetes mellitus, hypertension and dyslipidemia is&#xD;
      53,9%, 40%, 80% and 40,3% post lung transplantation. Tremor is one of the most common CNI&#xD;
      induced neurological toxic effect, besides polyneuropathy, headaches, insomnia, vertigo,&#xD;
      dysesthesia and reduced cognitive ability. These complications are, among others, attributed&#xD;
      to high peak serum tacrolimuslevels, whereas the effectiveness of the drug is determined by&#xD;
      the area under the curve. In general lung transplant recipients have higher peak and trough&#xD;
      levels when compared to other solid organ transplant recipients and therefore potentially&#xD;
      experience more severe toxic side effects.&#xD;
&#xD;
      Since a few years an once daily extended release tacrolimus has been introduced in solid&#xD;
      organ transplantation. The advantage of extended release tacrolimus is its prolonged release&#xD;
      and higher bioavailability than other tacrolimus formulations. This result in lower peaks,&#xD;
      more stable serum levels over 24 hours, and less fluctuation of blood concentrations. In&#xD;
      addition, for an equal overall systemic tacrolimus exposure a 30% lower dosage is needed for&#xD;
      extended release tacrolimus when compared to other formulations. In kidney and liver&#xD;
      transplantation, extended release tacrolimus is safe and effective. Langone et al&#xD;
      demonstrated in an enriched population of kidney transplant patients with tremor, that&#xD;
      extended release tacrolimus improved hand tremor compared to immediate release tacrolimus.&#xD;
&#xD;
      Long-term toxicity outcome of extended release tacrolimus after lung transplantation has not&#xD;
      been studied so far. Therefore the potential benefit of exteded release tacrolimus in de novo&#xD;
      and stable post-lung transplant recipients should be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>De novo cohort, 2 arms: de novo lung transplant recipients. Conversion cohort, 2 arms: stable lung transplant recipients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal function: absolute change in eGFR</measure>
    <time_frame>2 years</time_frame>
    <description>absolute change in eGFR absolute change in eGFR change in eGFR at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>graft function</measure>
    <time_frame>2 years</time_frame>
    <description>Acute graft dysfunction is a clinical diagnoses, with or without histological confirmation, and indictation for rejection treatment such as methylprednisolon. Chronic graft dysfunction is defined according to the ISHLT guidelines, as a persistent decline (â‰¥20%) in measured FEV1 value from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function: 40% eGFR reduction</measure>
    <time_frame>2 years</time_frame>
    <description>40% eGFR reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function: 50% eGFR reduction</measure>
    <time_frame>2 years</time_frame>
    <description>50% eGFR reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function:end stage kidney disease</measure>
    <time_frame>2 years</time_frame>
    <description>end stage kidney disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypertension</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of inadequate regulated or new onset of hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diabetes mellitus</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of inadequate glycemic control of preexisting diabetes mellitus or new onset diabetes after transplantation (NODAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancies</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological function: tremor</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of or change in pre-existing hand tremor by using the validated Fahn-Tolosa-Martin (FTM) tremor rating scale (grades of tremor 0-4, in which 0 indicated no tremor and 4 severe tremor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological function: polyneuropathy</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of or change in pre-existing polyneuropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological function: sleep quality</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of or change in sleep quality by using validated questionnaire: Pittsburg Sleep Quality Index (PSQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological function: cognitive functioning</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of or change in cognitive functioning by using validated questionnaire: the Cognitive Functioning Questionnaire (CFQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>2 years</time_frame>
    <description>change in SF36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacogenetic</measure>
    <time_frame>2 years</time_frame>
    <description>explorative endpoints: effects of well known variances in CYP3A4, CYP3A5 and ABCB1 transporter function on tacrolimus metabolism (resulting in so-called slow and fast tacrolimus metabolisers) on long-term tacrolimus renal toxicity by using absolute eGFR change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacogenetic</measure>
    <time_frame>2 years</time_frame>
    <description>explorative endpoints: effects of well known variances in CYP3A4, CYP3A5 and ABCB1 transporter function on tacrolimus metabolism (resulting in so-called slow and fast tacrolimus metabolisers) on long-term tacrolimus neurological toxicity: change in incidence of or change in pre-existing hand tremor by using the validated Fahn-Tolosa-Martin tremor rating scale</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Lung Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>de novo cohort, extended release tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>de novo cohort, extended release tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>de novo cohort, immediate release tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>de novo cohort, immediate release tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conversion cohort, extended release tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>conversion cohort, extended release tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conversion cohort, immediate release tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conversion cohort, immediate release tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended release tacrolimus</intervention_name>
    <description>de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when &gt;1 year post-lungtransplantation and with stable graft function</description>
    <arm_group_label>conversion cohort, extended release tacrolimus</arm_group_label>
    <arm_group_label>de novo cohort, extended release tacrolimus</arm_group_label>
    <other_name>LCP tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate release tacrolimus</intervention_name>
    <description>de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when &gt;1 year post-lungtransplantation and with stable graft function</description>
    <arm_group_label>conversion cohort, immediate release tacrolimus</arm_group_label>
    <arm_group_label>de novo cohort, immediate release tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Single or bilateral lung transplantation&#xD;
&#xD;
          -  On twice daily tacrolimus with stable trough levels in target range&#xD;
&#xD;
          -  Participant in the TransplantLines biobank study in the UMCG&#xD;
&#xD;
        Additional criteria for Conversion cohort:&#xD;
&#xD;
          -  At least one year after lung transplantation with a stable clinical course and lung&#xD;
             function&#xD;
&#xD;
          -  eGFR &gt;30ml/min*1.73m2 calculated with the CKD-EPI formula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Administration of mTOR inhibitors; everolimus, sirolimus&#xD;
&#xD;
          -  Quadruple immunosuppression&#xD;
&#xD;
          -  Renal transplantation&#xD;
&#xD;
          -  The subject has any disease or condition that might interfere with completion of this&#xD;
             study or reaching the primary endpoint (e.g., life expectancy of &lt;3 years, renal&#xD;
             replacement therapy at start study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tji Gan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heleen Grootjans</last_name>
    <phone>0031503616161</phone>
    <email>h.grootjans@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tji Gan</last_name>
    <phone>0031503616161</phone>
    <email>c.t.gan@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University medical center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heleen Grootjans</last_name>
      <phone>0031503616161</phone>
    </contact>
    <investigator>
      <last_name>Tji Gan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heleen Grootjans</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Verschuuren</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Berger</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daan Touw</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Sintes H, SÃ¡ez-GimÃ©nez B, Berastegui C, LÃ³pez-Meseguer M, Monforte V, Bravo C, Vima J, GÃ³mez-OllÃ©s S, Roman A. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients. Transplantation. 2018 Oct;102(10):e439-e446. doi: 10.1097/TP.0000000000002348.</citation>
    <PMID>29965950</PMID>
  </results_reference>
  <results_reference>
    <citation>MÃ©ndez A, Berastegui C, LÃ³pez-Meseguer M, Monforte V, Bravo C, Blanco A, CamÃ³s S, Pou L, Roman A. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. Transplantation. 2014 Feb 15;97(3):358-62. doi: 10.1097/01.TP.0000435699.69266.66.</citation>
    <PMID>24492423</PMID>
  </results_reference>
  <results_reference>
    <citation>TruneÄŒka P, Klempnauer J, Bechstein WO, Pirenne J, Friman S, Zhao A, Isoniemi H, Rostaing L, Settmacher U, MÃ¶nch C, Brown M, Undre N, Tisone G; DIAMONDâ€  study group. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. Am J Transplant. 2015 Jul;15(7):1843-54. doi: 10.1111/ajt.13182. Epub 2015 Feb 23.</citation>
    <PMID>25707487</PMID>
  </results_reference>
  <results_reference>
    <citation>SÃ¡nchez Fructuoso A, Ruiz JC, Franco A, Diekmann F, Redondo D, CalviÃ±o J, Serra N, AladrÃ©n MJ, CigarrÃ¡n S, Manonelles A, Ramos A, GÃ³mez G, GonzÃ¡lez Posada JM, AndrÃ©s A, Beneyto I, MuÃ±iz AL, PerellÃ³ M, Lauzurica R. Effectiveness and safety of the conversion to MeltDose(Â®) extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study. Clin Transplant. 2020 Jan;34(1):e13767. doi: 10.1111/ctr.13767. Epub 2019 Dec 31.</citation>
    <PMID>31815310</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Heleen Grootjans</investigator_full_name>
    <investigator_title>Drs. Heleen Grootjans, internist-nephrologist</investigator_title>
  </responsible_party>
  <keyword>lung transplantation</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>extended release tacrolimus</keyword>
  <keyword>LCP tacrolimus</keyword>
  <keyword>immediate release tacrolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

